Latest News

Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea


The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.

I invested half of my son’s inheritance with a 13.5% return. A major broker underperformed the S&P 500 with the rest. Should I take over all his assets?

Previous article

Rent the Runway sees ‘milestone’ 2024 and breakeven cash flow, as stock soars

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News